Novartis and US government reach agreement on lowering drug prices in the US
arcticnovartis
Fri, 12/19/2025 – 20:34
Read more about Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to tak…
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis
Tue, 12/09/2025 – 13:34
Read more about Novartis ianalumab significantly extends disease control in …
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis
Tue, 12/09/2025 – 13:19
Read more about 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain pr…
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis
Tue, 11/25/2025 – 07:19
Read more about Novartis data underscore pioneering scientific innovation in hematology and oncology at AS…
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis
Mon, 11/24/2025 – 23:19
Read more about Novartis receives FDA appr…
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis
Thu, 11/20/2025 – 07:04
Read more about Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth…
